Korean J Urol.  2010 Jun;51(6):386-390.

Preoperative Clinical and Pathological Characteristics of pT0 Prostate Cancer in Radical Prostatectomy

• Park J
• Jeong IG
• Bang JK
• Cho YM
• Ro JY
• Hong JH
• Ahn H
• Kim CS

Abstract

PURPOSE
To analyze the preoperative clinical and pathological characteristics of patients with pT0 prostate cancer.
MATERIALS AND METHODS
We retrospectively reviewed the records of 702 patients who underwent radical prostatectomy (RP) at our institution between January 2004 and July 2008 for clinically localized prostate cancer. If there was no evidence of residual tumor in the pathological specimen of the prostate, a patient was staged as pT0. Patients with pT0 disease were compared with a control group of patients who were operated on during the same period.
RESULTS
Overall, 9 (1.3%) patients were staged as pT0 on the pathologic examination. Significant differences were observed between the pT0 group and the control patients in the biopsy Gleason score (p=0.004), the number of positive cores on biopsy (p=0.018), the tumor length of positive cores (p<0.001), and prostate volume (p=0.015). Cutoff values predictive of pT0 tumor status were defined as a biopsy Gleason score sum < or =6, 2 or fewer positive biopsy cores, tumor length on biopsy < or =2 mm, and prostate volume >30 cm3. Whereas 8 of the 9 (88.9%) pT0 patients showed all of these characteristics, only 55 of the 693 (7.9%) control patients fulfilled the criteria. The combination suggested above afforded a sensitivity of 88.8% and a specificity of 92.1% for the prediction of pT0 status.
CONCLUSIONS
The frequency of pT0 prostate cancer seen on RP was 1.3%. A combination of clinicopathological features, incorporating a biopsy Gleason score, the number of positive biopsy cores, tumor length on biopsy, and prostate volume, was useful to predict pT0 stage on RP.

Keyword

Biopsy; Neoplasm staging; Prostatectomy; Prostatic neoplasms

MeSH Terms

Biopsy
Humans
Neoplasm Grading
Neoplasm Staging
Neoplasm, Residual
Prostate
Prostatectomy
Prostatic Neoplasms
Retrospective Studies
Sensitivity and Specificity

Reference

1. Bostwick DG, Montironi R. Evaluating radical prostatectomy specimens: therapeutic and prognostic importance. Virchows Arch. 1997; 430:1–16. PMID: 9037309.

2. DiGiuseppe JA, Sauvageot J, Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol. 1997; 21:174–178. PMID: 9042283.

3. Goldstein NS, Begin LR, Grody WW, Novak JM, Qian J, Bostwick DG. Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the "vanishing cancer phenomenon". Am J Surg Pathol. 1995; 19:1002–1009. PMID: 7661273.

4. Noguchi M, Noda S, Nakashima O, Kojiro M. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer. Oncol Rep. 2002; 9:1075–1080. PMID: 12168076.

5. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol. 2000; 18:1050–1057. PMID: 10694556.

6. Pisters LL, Dinney CP, Pettaway CA, Scott SM, Babaian RJ, von Eschenbach AC, et al. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol. 1999; 161:509–514. PMID: 9915437.

7. Schulman CC. Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. Prostate Suppl. 1994; 5:9–14. PMID: 7513532.

8. Köllermann J, Caprano J, Budde A, Weidenfeld H, Weidenfeld M, Hopfenmüller W, et al. Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy. Urology. 2003; 62:476–480. PMID: 12946750.

9. Köllermann J, Feek U, Müller H, Kaulfuss U, Oehler U, Helpap B, et al. Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol. 2000; 38:714–720. PMID: 11111189.

10. Köllermann J, Hopfenmüller W, Caprano J, Budde A, Weidenfeld H, Weidenfeld M, et al. Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis. Eur Urol. 2004; 45:42–45. PMID: 14667514.

11. Bostwick DG, Bostwick KC. 'Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases. BJU Int. 2004; 94:57–58. PMID: 15217431.

12. Descazeaud A, Zerbib M, Flam T, Vieillefond A, Debre B, Peyromaure M. Can pT0 stage of prostate cancer be predicted before radical prostatectomy? Eur Urol. 2006; 50:1248–1252. PMID: 16828964.

13. Herkommer K, Kuefer R, Gschwend JE, Hautmann RE, Volkmer BG. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. Eur Urol. 2004; 45:36–41. PMID: 14667513.

14. Montironi R, Cheng L, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Mikuz G, et al. Stage pT0 in radical prostatectomy with no residual carcinoma and with a previous positive biopsy conveys a wrong message to clinicians and patients: why is cancer not present in the radical prostatectomy specimen? Eur Urol. 2009; 56:272–274. PMID: 19443101.

15. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol. 1995; 75:347–353. PMID: 7537604.

16. Song C, Ro JY, Lee MS, Hong SJ, Chung BH, Choi HY, et al. Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology. 2006; 68:820–824. PMID: 17070360.

17. Whittemore AS. Prostate cancer. Cancer Surv. 1994; 19-20:309–322. PMID: 7895221.

18. Bessede T, Soulie M, Mottet N, Rebillard X, Peyromaure M, Ravery V, et al. Stage pT0 after radical prostatectomy with previous positive biopsy sets: a multicenter study. J Urol. 2010; 183:958–962. PMID: 20083270.

19. Epstein JI, Paull G, Eggleston JC, Walsh PC. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol. 1986; 136:837–839. PMID: 3761442.

20. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007; 178:2359–2364. PMID: 17936806.